FABP5 and metastatic neoplasm: Mounting evidence has demonstrated that the expression level of FABP5 is low in low grade tumors and highly upregulated as the progression of the disease manifests to aggressive, metastatic tumors [51, 52, 87–89], clarifying the importance of a rational drug design targeting FABP5.